Atomoxetine: Novel Therapy for Attention-Deficit/Hyperactivity Disorder and Potential Therapeutic Implications

Primary Psychiatry

Volumn 10, Issue 4, 2003, Pages 41-48

  Sallee, Floyd R ^a,b   Smirnov, Alex ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; MENTAL HEALTH; MORBIDITY; PHARMACODYNAMICS; REVIEW; UROGENITAL TRACT DISEASE; XEROSTOMIA;

EID: 0347934632     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry. 2000;9(suppl 1):51-59.
2. Murphy K. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord. 1996;1:147-161.
3. Ingram LH, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. Ment Retard Devel Disabil Res Rev. 1999;5:243-250.
4. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
5. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company, 2002.
6. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
7. Lahey BB, Applegate B, McBurnett K, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry. 1994;151:1673-1685.
8. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd ed. New York, NY: Guilford Press; 1998.
9. Seidman LJ, Biederman J, Weber W, Hatch M, Faraone SV. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry. 1998;44:260-268.
10. Barkley KM, Kwasnik D. Psychological adjustment and adaptive impairments in young adults with ADHD. J Atten Disord. 1996;1:41-54.
11. De Quiros GB, Kinsbourne M. Adult ADHD. Analysis of self-ratings on a behavior questionnaire. Ann N Y Acad Sci. 2001;931:140-147.
12. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816-818.
13. Journal of Attention Disorders. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. Available at: http://www.mhs.com/jad/abstracts/year02.htm. Accessed: March 2003.
14. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorders in adults. Clin Neuropharmacol. 1985;8:343-356.
15. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry. 1984;41:1059-1063.
16. Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry. 2000;48:9-20.
17. Murphy KR, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord. 1996;1:147-161.
18. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546-557.
19. Hechtman LT, Weiss G. Hyperactive Children Grown Up. New York, NY: Guilford Press; 1993.
20. Weiss G, Hechtman LT. Hyperactive Children Grown Up: ADHD in Children Adolescents, and Adults. 2nd ed. New York, NY: Guilford Press; 1998.
21. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol. 2002;30:463-475.
22. Biederman J, Faraone SV, Knee D, Munir K. Retrospective assessment of DSM-III attention deficit disorder in nonreferred individuals. J Clin Psychiatry. 1990;51:102-106.
23. Manshadi M, Lippmann S, O'Daniel RG, Blackman A. Alcohol abuse and attention deficit disorder. J Clin Psychiatry. 1983;44:379-380.
24. Biederman J, Faraone SV, Mick E, et al. High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry. 1995;152:431-435.
25. Faraone S. Attention deficit hyperactivity disorder in adults: implications for theories of diagnosis. Curr Direc Psychol Sci. 2000;9:33-36.
26. Faraone SV, Biederman J, Mick E. Symptom reports by adults with attention deficit hyperactivity disorder are they influenced by attention deficit hyperactivity disorder in their children? J Nerv Ment Dis. 1997;185:583-584.
27. Goodman R. Genetic factors in hyperactivity. BMJ. 1989;298:1407-1408.
28. Thapar A, Hervas A, McGuffin P. Childhood hyperactivity scores are highly heritable and show sibling competition effects: twin study evidence. Behav Genet. 1995;25:537-544.
29. Goodman R, Stevenson J. A twin study of hyperactivity-I. An examination of hyperactivity scores and categories derived from Rutter teacher and parent questionnaires. J Child Psychol Psychiatry. 1989;30:671-689.
30. Goodman R, Stevenson J. A twin study of hyperactivity-II. The aetiological role of genes, family relationships and perinatal adversity. J Child Psychol Psychiatry. 1989;30:691-709.
31. Gilger JW, Pennington BF, DeFries JC. A twin study of the etiology of comorbidity: attention-deficit hyperactivity disorder and dyslexia. J Am Acad Child Adolesc Psychiatry. 1992;31:343-348.
32. Faraone SV, Biederman J, Weiffenbach B, et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156:768-770.
33. Silver LB. Attention-deficit/hyperactivity disorder in adult life. Child Adolesc Psychiatr Clin N Am. 2000;9:511-523.
34. Marks DJ, Newcorn JH, Halperin JM. Comorbidity in adults with attention-deficit/hyperactivity disorder. Ann N Y Acad Sci. 2001;931:216-238.
35. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98(6 Pt 1):1089-1095.
36. Murphy KRAB, Kwasnik D. Psychological adjustment and adaptive impairments in young adults with ADHD. J Atten Disord. 1996;1:41-54.
37. Satterfield JH, Schell A. A prospective study of hyperactive boys with conduct problems and normal boys: adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry. 1997;36:1726-1735.
38. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA. 2001;285:60-66.
39. Downey KK, Stelson FW, Pomerleau OF, Giordani B. Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population. J Nerv Ment Dis. 1997;185:32-38.
40. Heiligenstein E, Guenther G, Levy A, Savino F, Fulwiler J. Psychological and academic functioning in college students with attention deficit hyperactivity disorder. J Am Coll Health. 1999;47:181-185.
41. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792-1798.
42. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31:416-425.
43. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652-1658.
44. Spencer TJ, Biederman J, Faraone S, et al. Impact of tic disorders on ADHD outcome across the life cycle: findings from a large group of adults with and without ADHD. Am J Psychiatry. 2001;158:611-617.
45. Sergeant J. The cognitive-energetic model: an empirical approach to attention-deficit hyperactivity disorder. Neurosci Biobehav Rev. 2000;24:7-12.
46. Mirsky AF, Anthony BJ, Duncan CC, Ahearn MB, Kellam SG. Analysis of the elements of attention: a neuropsychological approach. Neuropsychol Rev. 1991;2:109-145.
47. Posner MI, Petersen SE. The attention system of the human brain. Annu Rev Neurosci. 1990;13:25-42.
48. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121:65-94.
49. Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Brown CR. EEG evidence for a new conceptualisation of attention deficit hyperactivity disorder. Clin Neurophysiol. 2002;113:1036-1044.
50. Jovicich J, Peters RJ, Koch C, Braun J, Chang L, Ernst T. Brain areas specific for attentional load in a motion-tracking task. J Cognit Neurosci. 2001;13:1048-1058.
51. Ernst M, Tata S. Review of functional imaging research in attention-deficit/hyperactivity disorder. TEN. 2001;3:58-66.
52. Bush G, Whalen PJ, Rosen BR, Jenike MA, McInerney SC, Rauch SL. The counting Stroop: an interference task specialized for functional neuroimaging-validation study with functional MRI. Hum Brain Mapp. 1998;6:270-282.
53. Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002;3:617-628.
54. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156:1209-1215.
55. Castellanos FX. Toward a pathophysiology of attention-deficit/hyperactivity disorder. Clin Pediatr (Phila). 1997;36:381-393.
56. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.
57. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry. 1996;35:264-272.
58. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104:20.
59. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775-782.
60. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434-443.
61. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153:1147-1153.
62. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 1990;147:1018-1020.
63. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282-288.
64. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001;13:129-134.
65. Hornig-Rohan M, Amsterdam JD. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:585-589.
66. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
67. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67:149-156.
68. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
69. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:83.
70. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
71. Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:75.
72. Newcorn JH. Bupropion for adults with attention deficit hyperactivity disorder. Curr Psychiatry Rep. 2002;4:86-87.
73. Newcorn JH. Amphetamine salt compound treatment for adults with attention deficit hyperactivity disorder. Curr Psychiatry Rep. 2002;4:85-86.
74. Bartlik B, Harmon G. Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma. Arch Gen Psychiatry. 1997;54:188-189.
75. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder an open clinical trial. J Clin Psychiatry. 1996;57:184-189.
76. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis. 2002;21:1-16.
77. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21:223-228.
78. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2001;21:116-118.
79. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.
80. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998;155:693-695.
81. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems; 1999.